Global Diabetic Macular Edema Treatment Market

Diabetic Macular Edema Treatment Comprehensive Study by Type (Laser Photocoagulation Therapy, Pharmacological Therapy, Bevacizumab, Ranibizumab, Triamcinolone), Indication (Diffuse Diabetic Macular Edema, Focal Diabetic Macular Edema), Drug Delivery (Intravitreal Injections, Intravitreal Implants), End User (Hospitals, Ophthalmic Clinics, Research Institutes, Contract Research Organizations) Players and Region - Global Market Outlook to 2028

Diabetic Macular Edema Treatment Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Diabetic Macular Edema Treatment
Advancements in ophthalmic surgery techniques, as well as pharmaceutical companies' R&D investments, will help to fuel numerous opportunities for the diabetic macular edema treatment market to expand. Diabetic macular edema (DME) is a buildup of fluid in the macula of the retina, which regulates the human eye's vision abilities. Diabetic retinopathy is a condition that is caused by DME. DME is one of the most common complications of diabetes, and DME patients use considerably more healthcare services than diabetic patients who do not have DME.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Diabetic Macular Edema Treatment market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

F. Hoffmann-La Roche AG (Switzerland), Novartis AG (Switzerland), GlaxoSmithKline plc (United Kingdom), Alimera Sciences, Inc. (United States), Allergan, Inc (Ireland), Regeneron Pharmaceuticals Inc. (United States), Pfizer Inc. (United States), Kubota Pharmaceutical Holdings Co. Ltd. (United States), Oculis (Switzerland) and Bayer AG (Germany) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Bausch & Lomb Incorporated (United States) and Jaeb Center for Health Research (United States).

Segmentation Overview
AMA Research has segmented the market of Global Diabetic Macular Edema Treatment market by Type (Laser Photocoagulation Therapy, Pharmacological Therapy, Bevacizumab, Ranibizumab and Triamcinolone) and Region.



On the basis of geography, the market of Diabetic Macular Edema Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Indication, the sub-segment i.e. Diffuse Diabetic Macular Edema will boost the Diabetic Macular Edema Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Drug Delivery, the sub-segment i.e. Intravitreal Injections will boost the Diabetic Macular Edema Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Hospitals will boost the Diabetic Macular Edema Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Surging R&D Investment by Pharmaceutical Companies in the Diabetic Macular Edema Treatment Field

Market Growth Drivers:
Increasing Prevalence of Diabetes and Rising Awareness for the Treatment of Diabetic Macular Edema

Challenges:
Dearth of Skilled Ophthalmologists and Extended Approval Time for Drugs

Restraints:
High Medical Costs for the Patients

Opportunities:
Lucrative Opportunities in the Emerging Economies and Advancement in Ophthalmic Surgery Techniques

Market Leaders and their expansionary development strategies
December 20, 2020, Genentech announced positive topline results from two identically designed global Phase III studies, YOSEMITE and RHINE, evaluating its investigational bispecific antibody, faricimab, in people living with diabetic macular edema (DME)
In Jan 2021, AsclepiX Therapeutics, Inc announced that the first patient has been dosed in the Phase 1/2a CONGO clinical trial to evaluate the safety and bioactivity of AXT107 in patients with Diabetic Macular Edema (DME)., and In Dec 2020, Novartis announced positive findings from the first interpretable results of the Phase III KESTREL study, assessing the efficacy and safety of Beovu® (brolucizumab) 3 mg and 6 mg in diabetic macular edema (DME).


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Diabetic Macular Edema Treatment Providers, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End-Use Industry

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Laser Photocoagulation Therapy
  • Pharmacological Therapy
  • Bevacizumab
  • Ranibizumab
  • Triamcinolone
By Indication
  • Diffuse Diabetic Macular Edema
  • Focal Diabetic Macular Edema

By Drug Delivery
  • Intravitreal Injections
  • Intravitreal Implants

By End User
  • Hospitals
  • Ophthalmic Clinics
  • Research Institutes
  • Contract Research Organizations

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Diabetes
      • 3.2.2. Rising Awareness for the Treatment of Diabetic Macular Edema
    • 3.3. Market Challenges
      • 3.3.1. Dearth of Skilled Ophthalmologists
      • 3.3.2. Extended Approval Time for Drugs
    • 3.4. Market Trends
      • 3.4.1. Surging R&D Investment by Pharmaceutical Companies in the Diabetic Macular Edema Treatment Field
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Diabetic Macular Edema Treatment, by Type, Indication, Drug Delivery, End User and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Diabetic Macular Edema Treatment (Value)
      • 5.2.1. Global Diabetic Macular Edema Treatment by: Type (Value)
        • 5.2.1.1. Laser Photocoagulation Therapy
        • 5.2.1.2. Pharmacological Therapy
        • 5.2.1.3. Bevacizumab
        • 5.2.1.4. Ranibizumab
        • 5.2.1.5. Triamcinolone
      • 5.2.2. Global Diabetic Macular Edema Treatment by: Indication (Value)
        • 5.2.2.1. Diffuse Diabetic Macular Edema
        • 5.2.2.2. Focal Diabetic Macular Edema
      • 5.2.3. Global Diabetic Macular Edema Treatment by: Drug Delivery (Value)
        • 5.2.3.1. Intravitreal Injections
        • 5.2.3.2. Intravitreal Implants
      • 5.2.4. Global Diabetic Macular Edema Treatment by: End User (Value)
        • 5.2.4.1. Hospitals
        • 5.2.4.2. Ophthalmic Clinics
        • 5.2.4.3. Research Institutes
        • 5.2.4.4. Contract Research Organizations
      • 5.2.5. Global Diabetic Macular Edema Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Diabetic Macular Edema Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. F. Hoffmann-La Roche AG (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Novartis AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. GlaxoSmithKline plc (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Alimera Sciences, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Allergan, Inc (Ireland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Regeneron Pharmaceuticals Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Pfizer Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Kubota Pharmaceutical Holdings Co. Ltd. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Oculis (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Bayer AG (Germany)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Diabetic Macular Edema Treatment Sale, by Type, Indication, Drug Delivery, End User and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Diabetic Macular Edema Treatment (Value)
      • 7.2.1. Global Diabetic Macular Edema Treatment by: Type (Value)
        • 7.2.1.1. Laser Photocoagulation Therapy
        • 7.2.1.2. Pharmacological Therapy
        • 7.2.1.3. Bevacizumab
        • 7.2.1.4. Ranibizumab
        • 7.2.1.5. Triamcinolone
      • 7.2.2. Global Diabetic Macular Edema Treatment by: Indication (Value)
        • 7.2.2.1. Diffuse Diabetic Macular Edema
        • 7.2.2.2. Focal Diabetic Macular Edema
      • 7.2.3. Global Diabetic Macular Edema Treatment by: Drug Delivery (Value)
        • 7.2.3.1. Intravitreal Injections
        • 7.2.3.2. Intravitreal Implants
      • 7.2.4. Global Diabetic Macular Edema Treatment by: End User (Value)
        • 7.2.4.1. Hospitals
        • 7.2.4.2. Ophthalmic Clinics
        • 7.2.4.3. Research Institutes
        • 7.2.4.4. Contract Research Organizations
      • 7.2.5. Global Diabetic Macular Edema Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Diabetic Macular Edema Treatment: by Type(USD Million)
  • Table 2. Diabetic Macular Edema Treatment Laser Photocoagulation Therapy , by Region USD Million (2017-2022)
  • Table 3. Diabetic Macular Edema Treatment Pharmacological Therapy , by Region USD Million (2017-2022)
  • Table 4. Diabetic Macular Edema Treatment Bevacizumab , by Region USD Million (2017-2022)
  • Table 5. Diabetic Macular Edema Treatment Ranibizumab , by Region USD Million (2017-2022)
  • Table 6. Diabetic Macular Edema Treatment Triamcinolone , by Region USD Million (2017-2022)
  • Table 7. Diabetic Macular Edema Treatment: by Indication(USD Million)
  • Table 8. Diabetic Macular Edema Treatment Diffuse Diabetic Macular Edema , by Region USD Million (2017-2022)
  • Table 9. Diabetic Macular Edema Treatment Focal Diabetic Macular Edema , by Region USD Million (2017-2022)
  • Table 10. Diabetic Macular Edema Treatment: by Drug Delivery(USD Million)
  • Table 11. Diabetic Macular Edema Treatment Intravitreal Injections , by Region USD Million (2017-2022)
  • Table 12. Diabetic Macular Edema Treatment Intravitreal Implants , by Region USD Million (2017-2022)
  • Table 13. Diabetic Macular Edema Treatment: by End User(USD Million)
  • Table 14. Diabetic Macular Edema Treatment Hospitals , by Region USD Million (2017-2022)
  • Table 15. Diabetic Macular Edema Treatment Ophthalmic Clinics , by Region USD Million (2017-2022)
  • Table 16. Diabetic Macular Edema Treatment Research Institutes , by Region USD Million (2017-2022)
  • Table 17. Diabetic Macular Edema Treatment Contract Research Organizations , by Region USD Million (2017-2022)
  • Table 18. South America Diabetic Macular Edema Treatment, by Country USD Million (2017-2022)
  • Table 19. South America Diabetic Macular Edema Treatment, by Type USD Million (2017-2022)
  • Table 20. South America Diabetic Macular Edema Treatment, by Indication USD Million (2017-2022)
  • Table 21. South America Diabetic Macular Edema Treatment, by Drug Delivery USD Million (2017-2022)
  • Table 22. South America Diabetic Macular Edema Treatment, by End User USD Million (2017-2022)
  • Table 23. Brazil Diabetic Macular Edema Treatment, by Type USD Million (2017-2022)
  • Table 24. Brazil Diabetic Macular Edema Treatment, by Indication USD Million (2017-2022)
  • Table 25. Brazil Diabetic Macular Edema Treatment, by Drug Delivery USD Million (2017-2022)
  • Table 26. Brazil Diabetic Macular Edema Treatment, by End User USD Million (2017-2022)
  • Table 27. Argentina Diabetic Macular Edema Treatment, by Type USD Million (2017-2022)
  • Table 28. Argentina Diabetic Macular Edema Treatment, by Indication USD Million (2017-2022)
  • Table 29. Argentina Diabetic Macular Edema Treatment, by Drug Delivery USD Million (2017-2022)
  • Table 30. Argentina Diabetic Macular Edema Treatment, by End User USD Million (2017-2022)
  • Table 31. Rest of South America Diabetic Macular Edema Treatment, by Type USD Million (2017-2022)
  • Table 32. Rest of South America Diabetic Macular Edema Treatment, by Indication USD Million (2017-2022)
  • Table 33. Rest of South America Diabetic Macular Edema Treatment, by Drug Delivery USD Million (2017-2022)
  • Table 34. Rest of South America Diabetic Macular Edema Treatment, by End User USD Million (2017-2022)
  • Table 35. Asia Pacific Diabetic Macular Edema Treatment, by Country USD Million (2017-2022)
  • Table 36. Asia Pacific Diabetic Macular Edema Treatment, by Type USD Million (2017-2022)
  • Table 37. Asia Pacific Diabetic Macular Edema Treatment, by Indication USD Million (2017-2022)
  • Table 38. Asia Pacific Diabetic Macular Edema Treatment, by Drug Delivery USD Million (2017-2022)
  • Table 39. Asia Pacific Diabetic Macular Edema Treatment, by End User USD Million (2017-2022)
  • Table 40. China Diabetic Macular Edema Treatment, by Type USD Million (2017-2022)
  • Table 41. China Diabetic Macular Edema Treatment, by Indication USD Million (2017-2022)
  • Table 42. China Diabetic Macular Edema Treatment, by Drug Delivery USD Million (2017-2022)
  • Table 43. China Diabetic Macular Edema Treatment, by End User USD Million (2017-2022)
  • Table 44. Japan Diabetic Macular Edema Treatment, by Type USD Million (2017-2022)
  • Table 45. Japan Diabetic Macular Edema Treatment, by Indication USD Million (2017-2022)
  • Table 46. Japan Diabetic Macular Edema Treatment, by Drug Delivery USD Million (2017-2022)
  • Table 47. Japan Diabetic Macular Edema Treatment, by End User USD Million (2017-2022)
  • Table 48. India Diabetic Macular Edema Treatment, by Type USD Million (2017-2022)
  • Table 49. India Diabetic Macular Edema Treatment, by Indication USD Million (2017-2022)
  • Table 50. India Diabetic Macular Edema Treatment, by Drug Delivery USD Million (2017-2022)
  • Table 51. India Diabetic Macular Edema Treatment, by End User USD Million (2017-2022)
  • Table 52. South Korea Diabetic Macular Edema Treatment, by Type USD Million (2017-2022)
  • Table 53. South Korea Diabetic Macular Edema Treatment, by Indication USD Million (2017-2022)
  • Table 54. South Korea Diabetic Macular Edema Treatment, by Drug Delivery USD Million (2017-2022)
  • Table 55. South Korea Diabetic Macular Edema Treatment, by End User USD Million (2017-2022)
  • Table 56. Taiwan Diabetic Macular Edema Treatment, by Type USD Million (2017-2022)
  • Table 57. Taiwan Diabetic Macular Edema Treatment, by Indication USD Million (2017-2022)
  • Table 58. Taiwan Diabetic Macular Edema Treatment, by Drug Delivery USD Million (2017-2022)
  • Table 59. Taiwan Diabetic Macular Edema Treatment, by End User USD Million (2017-2022)
  • Table 60. Australia Diabetic Macular Edema Treatment, by Type USD Million (2017-2022)
  • Table 61. Australia Diabetic Macular Edema Treatment, by Indication USD Million (2017-2022)
  • Table 62. Australia Diabetic Macular Edema Treatment, by Drug Delivery USD Million (2017-2022)
  • Table 63. Australia Diabetic Macular Edema Treatment, by End User USD Million (2017-2022)
  • Table 64. Rest of Asia-Pacific Diabetic Macular Edema Treatment, by Type USD Million (2017-2022)
  • Table 65. Rest of Asia-Pacific Diabetic Macular Edema Treatment, by Indication USD Million (2017-2022)
  • Table 66. Rest of Asia-Pacific Diabetic Macular Edema Treatment, by Drug Delivery USD Million (2017-2022)
  • Table 67. Rest of Asia-Pacific Diabetic Macular Edema Treatment, by End User USD Million (2017-2022)
  • Table 68. Europe Diabetic Macular Edema Treatment, by Country USD Million (2017-2022)
  • Table 69. Europe Diabetic Macular Edema Treatment, by Type USD Million (2017-2022)
  • Table 70. Europe Diabetic Macular Edema Treatment, by Indication USD Million (2017-2022)
  • Table 71. Europe Diabetic Macular Edema Treatment, by Drug Delivery USD Million (2017-2022)
  • Table 72. Europe Diabetic Macular Edema Treatment, by End User USD Million (2017-2022)
  • Table 73. Germany Diabetic Macular Edema Treatment, by Type USD Million (2017-2022)
  • Table 74. Germany Diabetic Macular Edema Treatment, by Indication USD Million (2017-2022)
  • Table 75. Germany Diabetic Macular Edema Treatment, by Drug Delivery USD Million (2017-2022)
  • Table 76. Germany Diabetic Macular Edema Treatment, by End User USD Million (2017-2022)
  • Table 77. France Diabetic Macular Edema Treatment, by Type USD Million (2017-2022)
  • Table 78. France Diabetic Macular Edema Treatment, by Indication USD Million (2017-2022)
  • Table 79. France Diabetic Macular Edema Treatment, by Drug Delivery USD Million (2017-2022)
  • Table 80. France Diabetic Macular Edema Treatment, by End User USD Million (2017-2022)
  • Table 81. Italy Diabetic Macular Edema Treatment, by Type USD Million (2017-2022)
  • Table 82. Italy Diabetic Macular Edema Treatment, by Indication USD Million (2017-2022)
  • Table 83. Italy Diabetic Macular Edema Treatment, by Drug Delivery USD Million (2017-2022)
  • Table 84. Italy Diabetic Macular Edema Treatment, by End User USD Million (2017-2022)
  • Table 85. United Kingdom Diabetic Macular Edema Treatment, by Type USD Million (2017-2022)
  • Table 86. United Kingdom Diabetic Macular Edema Treatment, by Indication USD Million (2017-2022)
  • Table 87. United Kingdom Diabetic Macular Edema Treatment, by Drug Delivery USD Million (2017-2022)
  • Table 88. United Kingdom Diabetic Macular Edema Treatment, by End User USD Million (2017-2022)
  • Table 89. Netherlands Diabetic Macular Edema Treatment, by Type USD Million (2017-2022)
  • Table 90. Netherlands Diabetic Macular Edema Treatment, by Indication USD Million (2017-2022)
  • Table 91. Netherlands Diabetic Macular Edema Treatment, by Drug Delivery USD Million (2017-2022)
  • Table 92. Netherlands Diabetic Macular Edema Treatment, by End User USD Million (2017-2022)
  • Table 93. Rest of Europe Diabetic Macular Edema Treatment, by Type USD Million (2017-2022)
  • Table 94. Rest of Europe Diabetic Macular Edema Treatment, by Indication USD Million (2017-2022)
  • Table 95. Rest of Europe Diabetic Macular Edema Treatment, by Drug Delivery USD Million (2017-2022)
  • Table 96. Rest of Europe Diabetic Macular Edema Treatment, by End User USD Million (2017-2022)
  • Table 97. MEA Diabetic Macular Edema Treatment, by Country USD Million (2017-2022)
  • Table 98. MEA Diabetic Macular Edema Treatment, by Type USD Million (2017-2022)
  • Table 99. MEA Diabetic Macular Edema Treatment, by Indication USD Million (2017-2022)
  • Table 100. MEA Diabetic Macular Edema Treatment, by Drug Delivery USD Million (2017-2022)
  • Table 101. MEA Diabetic Macular Edema Treatment, by End User USD Million (2017-2022)
  • Table 102. Middle East Diabetic Macular Edema Treatment, by Type USD Million (2017-2022)
  • Table 103. Middle East Diabetic Macular Edema Treatment, by Indication USD Million (2017-2022)
  • Table 104. Middle East Diabetic Macular Edema Treatment, by Drug Delivery USD Million (2017-2022)
  • Table 105. Middle East Diabetic Macular Edema Treatment, by End User USD Million (2017-2022)
  • Table 106. Africa Diabetic Macular Edema Treatment, by Type USD Million (2017-2022)
  • Table 107. Africa Diabetic Macular Edema Treatment, by Indication USD Million (2017-2022)
  • Table 108. Africa Diabetic Macular Edema Treatment, by Drug Delivery USD Million (2017-2022)
  • Table 109. Africa Diabetic Macular Edema Treatment, by End User USD Million (2017-2022)
  • Table 110. North America Diabetic Macular Edema Treatment, by Country USD Million (2017-2022)
  • Table 111. North America Diabetic Macular Edema Treatment, by Type USD Million (2017-2022)
  • Table 112. North America Diabetic Macular Edema Treatment, by Indication USD Million (2017-2022)
  • Table 113. North America Diabetic Macular Edema Treatment, by Drug Delivery USD Million (2017-2022)
  • Table 114. North America Diabetic Macular Edema Treatment, by End User USD Million (2017-2022)
  • Table 115. United States Diabetic Macular Edema Treatment, by Type USD Million (2017-2022)
  • Table 116. United States Diabetic Macular Edema Treatment, by Indication USD Million (2017-2022)
  • Table 117. United States Diabetic Macular Edema Treatment, by Drug Delivery USD Million (2017-2022)
  • Table 118. United States Diabetic Macular Edema Treatment, by End User USD Million (2017-2022)
  • Table 119. Canada Diabetic Macular Edema Treatment, by Type USD Million (2017-2022)
  • Table 120. Canada Diabetic Macular Edema Treatment, by Indication USD Million (2017-2022)
  • Table 121. Canada Diabetic Macular Edema Treatment, by Drug Delivery USD Million (2017-2022)
  • Table 122. Canada Diabetic Macular Edema Treatment, by End User USD Million (2017-2022)
  • Table 123. Mexico Diabetic Macular Edema Treatment, by Type USD Million (2017-2022)
  • Table 124. Mexico Diabetic Macular Edema Treatment, by Indication USD Million (2017-2022)
  • Table 125. Mexico Diabetic Macular Edema Treatment, by Drug Delivery USD Million (2017-2022)
  • Table 126. Mexico Diabetic Macular Edema Treatment, by End User USD Million (2017-2022)
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Diabetic Macular Edema Treatment: by Type(USD Million)
  • Table 138. Diabetic Macular Edema Treatment Laser Photocoagulation Therapy , by Region USD Million (2023-2028)
  • Table 139. Diabetic Macular Edema Treatment Pharmacological Therapy , by Region USD Million (2023-2028)
  • Table 140. Diabetic Macular Edema Treatment Bevacizumab , by Region USD Million (2023-2028)
  • Table 141. Diabetic Macular Edema Treatment Ranibizumab , by Region USD Million (2023-2028)
  • Table 142. Diabetic Macular Edema Treatment Triamcinolone , by Region USD Million (2023-2028)
  • Table 143. Diabetic Macular Edema Treatment: by Indication(USD Million)
  • Table 144. Diabetic Macular Edema Treatment Diffuse Diabetic Macular Edema , by Region USD Million (2023-2028)
  • Table 145. Diabetic Macular Edema Treatment Focal Diabetic Macular Edema , by Region USD Million (2023-2028)
  • Table 146. Diabetic Macular Edema Treatment: by Drug Delivery(USD Million)
  • Table 147. Diabetic Macular Edema Treatment Intravitreal Injections , by Region USD Million (2023-2028)
  • Table 148. Diabetic Macular Edema Treatment Intravitreal Implants , by Region USD Million (2023-2028)
  • Table 149. Diabetic Macular Edema Treatment: by End User(USD Million)
  • Table 150. Diabetic Macular Edema Treatment Hospitals , by Region USD Million (2023-2028)
  • Table 151. Diabetic Macular Edema Treatment Ophthalmic Clinics , by Region USD Million (2023-2028)
  • Table 152. Diabetic Macular Edema Treatment Research Institutes , by Region USD Million (2023-2028)
  • Table 153. Diabetic Macular Edema Treatment Contract Research Organizations , by Region USD Million (2023-2028)
  • Table 154. South America Diabetic Macular Edema Treatment, by Country USD Million (2023-2028)
  • Table 155. South America Diabetic Macular Edema Treatment, by Type USD Million (2023-2028)
  • Table 156. South America Diabetic Macular Edema Treatment, by Indication USD Million (2023-2028)
  • Table 157. South America Diabetic Macular Edema Treatment, by Drug Delivery USD Million (2023-2028)
  • Table 158. South America Diabetic Macular Edema Treatment, by End User USD Million (2023-2028)
  • Table 159. Brazil Diabetic Macular Edema Treatment, by Type USD Million (2023-2028)
  • Table 160. Brazil Diabetic Macular Edema Treatment, by Indication USD Million (2023-2028)
  • Table 161. Brazil Diabetic Macular Edema Treatment, by Drug Delivery USD Million (2023-2028)
  • Table 162. Brazil Diabetic Macular Edema Treatment, by End User USD Million (2023-2028)
  • Table 163. Argentina Diabetic Macular Edema Treatment, by Type USD Million (2023-2028)
  • Table 164. Argentina Diabetic Macular Edema Treatment, by Indication USD Million (2023-2028)
  • Table 165. Argentina Diabetic Macular Edema Treatment, by Drug Delivery USD Million (2023-2028)
  • Table 166. Argentina Diabetic Macular Edema Treatment, by End User USD Million (2023-2028)
  • Table 167. Rest of South America Diabetic Macular Edema Treatment, by Type USD Million (2023-2028)
  • Table 168. Rest of South America Diabetic Macular Edema Treatment, by Indication USD Million (2023-2028)
  • Table 169. Rest of South America Diabetic Macular Edema Treatment, by Drug Delivery USD Million (2023-2028)
  • Table 170. Rest of South America Diabetic Macular Edema Treatment, by End User USD Million (2023-2028)
  • Table 171. Asia Pacific Diabetic Macular Edema Treatment, by Country USD Million (2023-2028)
  • Table 172. Asia Pacific Diabetic Macular Edema Treatment, by Type USD Million (2023-2028)
  • Table 173. Asia Pacific Diabetic Macular Edema Treatment, by Indication USD Million (2023-2028)
  • Table 174. Asia Pacific Diabetic Macular Edema Treatment, by Drug Delivery USD Million (2023-2028)
  • Table 175. Asia Pacific Diabetic Macular Edema Treatment, by End User USD Million (2023-2028)
  • Table 176. China Diabetic Macular Edema Treatment, by Type USD Million (2023-2028)
  • Table 177. China Diabetic Macular Edema Treatment, by Indication USD Million (2023-2028)
  • Table 178. China Diabetic Macular Edema Treatment, by Drug Delivery USD Million (2023-2028)
  • Table 179. China Diabetic Macular Edema Treatment, by End User USD Million (2023-2028)
  • Table 180. Japan Diabetic Macular Edema Treatment, by Type USD Million (2023-2028)
  • Table 181. Japan Diabetic Macular Edema Treatment, by Indication USD Million (2023-2028)
  • Table 182. Japan Diabetic Macular Edema Treatment, by Drug Delivery USD Million (2023-2028)
  • Table 183. Japan Diabetic Macular Edema Treatment, by End User USD Million (2023-2028)
  • Table 184. India Diabetic Macular Edema Treatment, by Type USD Million (2023-2028)
  • Table 185. India Diabetic Macular Edema Treatment, by Indication USD Million (2023-2028)
  • Table 186. India Diabetic Macular Edema Treatment, by Drug Delivery USD Million (2023-2028)
  • Table 187. India Diabetic Macular Edema Treatment, by End User USD Million (2023-2028)
  • Table 188. South Korea Diabetic Macular Edema Treatment, by Type USD Million (2023-2028)
  • Table 189. South Korea Diabetic Macular Edema Treatment, by Indication USD Million (2023-2028)
  • Table 190. South Korea Diabetic Macular Edema Treatment, by Drug Delivery USD Million (2023-2028)
  • Table 191. South Korea Diabetic Macular Edema Treatment, by End User USD Million (2023-2028)
  • Table 192. Taiwan Diabetic Macular Edema Treatment, by Type USD Million (2023-2028)
  • Table 193. Taiwan Diabetic Macular Edema Treatment, by Indication USD Million (2023-2028)
  • Table 194. Taiwan Diabetic Macular Edema Treatment, by Drug Delivery USD Million (2023-2028)
  • Table 195. Taiwan Diabetic Macular Edema Treatment, by End User USD Million (2023-2028)
  • Table 196. Australia Diabetic Macular Edema Treatment, by Type USD Million (2023-2028)
  • Table 197. Australia Diabetic Macular Edema Treatment, by Indication USD Million (2023-2028)
  • Table 198. Australia Diabetic Macular Edema Treatment, by Drug Delivery USD Million (2023-2028)
  • Table 199. Australia Diabetic Macular Edema Treatment, by End User USD Million (2023-2028)
  • Table 200. Rest of Asia-Pacific Diabetic Macular Edema Treatment, by Type USD Million (2023-2028)
  • Table 201. Rest of Asia-Pacific Diabetic Macular Edema Treatment, by Indication USD Million (2023-2028)
  • Table 202. Rest of Asia-Pacific Diabetic Macular Edema Treatment, by Drug Delivery USD Million (2023-2028)
  • Table 203. Rest of Asia-Pacific Diabetic Macular Edema Treatment, by End User USD Million (2023-2028)
  • Table 204. Europe Diabetic Macular Edema Treatment, by Country USD Million (2023-2028)
  • Table 205. Europe Diabetic Macular Edema Treatment, by Type USD Million (2023-2028)
  • Table 206. Europe Diabetic Macular Edema Treatment, by Indication USD Million (2023-2028)
  • Table 207. Europe Diabetic Macular Edema Treatment, by Drug Delivery USD Million (2023-2028)
  • Table 208. Europe Diabetic Macular Edema Treatment, by End User USD Million (2023-2028)
  • Table 209. Germany Diabetic Macular Edema Treatment, by Type USD Million (2023-2028)
  • Table 210. Germany Diabetic Macular Edema Treatment, by Indication USD Million (2023-2028)
  • Table 211. Germany Diabetic Macular Edema Treatment, by Drug Delivery USD Million (2023-2028)
  • Table 212. Germany Diabetic Macular Edema Treatment, by End User USD Million (2023-2028)
  • Table 213. France Diabetic Macular Edema Treatment, by Type USD Million (2023-2028)
  • Table 214. France Diabetic Macular Edema Treatment, by Indication USD Million (2023-2028)
  • Table 215. France Diabetic Macular Edema Treatment, by Drug Delivery USD Million (2023-2028)
  • Table 216. France Diabetic Macular Edema Treatment, by End User USD Million (2023-2028)
  • Table 217. Italy Diabetic Macular Edema Treatment, by Type USD Million (2023-2028)
  • Table 218. Italy Diabetic Macular Edema Treatment, by Indication USD Million (2023-2028)
  • Table 219. Italy Diabetic Macular Edema Treatment, by Drug Delivery USD Million (2023-2028)
  • Table 220. Italy Diabetic Macular Edema Treatment, by End User USD Million (2023-2028)
  • Table 221. United Kingdom Diabetic Macular Edema Treatment, by Type USD Million (2023-2028)
  • Table 222. United Kingdom Diabetic Macular Edema Treatment, by Indication USD Million (2023-2028)
  • Table 223. United Kingdom Diabetic Macular Edema Treatment, by Drug Delivery USD Million (2023-2028)
  • Table 224. United Kingdom Diabetic Macular Edema Treatment, by End User USD Million (2023-2028)
  • Table 225. Netherlands Diabetic Macular Edema Treatment, by Type USD Million (2023-2028)
  • Table 226. Netherlands Diabetic Macular Edema Treatment, by Indication USD Million (2023-2028)
  • Table 227. Netherlands Diabetic Macular Edema Treatment, by Drug Delivery USD Million (2023-2028)
  • Table 228. Netherlands Diabetic Macular Edema Treatment, by End User USD Million (2023-2028)
  • Table 229. Rest of Europe Diabetic Macular Edema Treatment, by Type USD Million (2023-2028)
  • Table 230. Rest of Europe Diabetic Macular Edema Treatment, by Indication USD Million (2023-2028)
  • Table 231. Rest of Europe Diabetic Macular Edema Treatment, by Drug Delivery USD Million (2023-2028)
  • Table 232. Rest of Europe Diabetic Macular Edema Treatment, by End User USD Million (2023-2028)
  • Table 233. MEA Diabetic Macular Edema Treatment, by Country USD Million (2023-2028)
  • Table 234. MEA Diabetic Macular Edema Treatment, by Type USD Million (2023-2028)
  • Table 235. MEA Diabetic Macular Edema Treatment, by Indication USD Million (2023-2028)
  • Table 236. MEA Diabetic Macular Edema Treatment, by Drug Delivery USD Million (2023-2028)
  • Table 237. MEA Diabetic Macular Edema Treatment, by End User USD Million (2023-2028)
  • Table 238. Middle East Diabetic Macular Edema Treatment, by Type USD Million (2023-2028)
  • Table 239. Middle East Diabetic Macular Edema Treatment, by Indication USD Million (2023-2028)
  • Table 240. Middle East Diabetic Macular Edema Treatment, by Drug Delivery USD Million (2023-2028)
  • Table 241. Middle East Diabetic Macular Edema Treatment, by End User USD Million (2023-2028)
  • Table 242. Africa Diabetic Macular Edema Treatment, by Type USD Million (2023-2028)
  • Table 243. Africa Diabetic Macular Edema Treatment, by Indication USD Million (2023-2028)
  • Table 244. Africa Diabetic Macular Edema Treatment, by Drug Delivery USD Million (2023-2028)
  • Table 245. Africa Diabetic Macular Edema Treatment, by End User USD Million (2023-2028)
  • Table 246. North America Diabetic Macular Edema Treatment, by Country USD Million (2023-2028)
  • Table 247. North America Diabetic Macular Edema Treatment, by Type USD Million (2023-2028)
  • Table 248. North America Diabetic Macular Edema Treatment, by Indication USD Million (2023-2028)
  • Table 249. North America Diabetic Macular Edema Treatment, by Drug Delivery USD Million (2023-2028)
  • Table 250. North America Diabetic Macular Edema Treatment, by End User USD Million (2023-2028)
  • Table 251. United States Diabetic Macular Edema Treatment, by Type USD Million (2023-2028)
  • Table 252. United States Diabetic Macular Edema Treatment, by Indication USD Million (2023-2028)
  • Table 253. United States Diabetic Macular Edema Treatment, by Drug Delivery USD Million (2023-2028)
  • Table 254. United States Diabetic Macular Edema Treatment, by End User USD Million (2023-2028)
  • Table 255. Canada Diabetic Macular Edema Treatment, by Type USD Million (2023-2028)
  • Table 256. Canada Diabetic Macular Edema Treatment, by Indication USD Million (2023-2028)
  • Table 257. Canada Diabetic Macular Edema Treatment, by Drug Delivery USD Million (2023-2028)
  • Table 258. Canada Diabetic Macular Edema Treatment, by End User USD Million (2023-2028)
  • Table 259. Mexico Diabetic Macular Edema Treatment, by Type USD Million (2023-2028)
  • Table 260. Mexico Diabetic Macular Edema Treatment, by Indication USD Million (2023-2028)
  • Table 261. Mexico Diabetic Macular Edema Treatment, by Drug Delivery USD Million (2023-2028)
  • Table 262. Mexico Diabetic Macular Edema Treatment, by End User USD Million (2023-2028)
  • Table 263. Research Programs/Design for This Report
  • Table 264. Key Data Information from Secondary Sources
  • Table 265. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Diabetic Macular Edema Treatment: by Type USD Million (2017-2022)
  • Figure 5. Global Diabetic Macular Edema Treatment: by Indication USD Million (2017-2022)
  • Figure 6. Global Diabetic Macular Edema Treatment: by Drug Delivery USD Million (2017-2022)
  • Figure 7. Global Diabetic Macular Edema Treatment: by End User USD Million (2017-2022)
  • Figure 8. South America Diabetic Macular Edema Treatment Share (%), by Country
  • Figure 9. Asia Pacific Diabetic Macular Edema Treatment Share (%), by Country
  • Figure 10. Europe Diabetic Macular Edema Treatment Share (%), by Country
  • Figure 11. MEA Diabetic Macular Edema Treatment Share (%), by Country
  • Figure 12. North America Diabetic Macular Edema Treatment Share (%), by Country
  • Figure 13. Global Diabetic Macular Edema Treatment share by Players 2022 (%)
  • Figure 14. Global Diabetic Macular Edema Treatment share by Players (Top 3) 2022(%)
  • Figure 15. Global Diabetic Macular Edema Treatment share by Players (Top 5) 2022(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. F. Hoffmann-La Roche AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 18. F. Hoffmann-La Roche AG (Switzerland) Revenue: by Geography 2022
  • Figure 19. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 20. Novartis AG (Switzerland) Revenue: by Geography 2022
  • Figure 21. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 22. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2022
  • Figure 23. Alimera Sciences, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Alimera Sciences, Inc. (United States) Revenue: by Geography 2022
  • Figure 25. Allergan, Inc (Ireland) Revenue, Net Income and Gross profit
  • Figure 26. Allergan, Inc (Ireland) Revenue: by Geography 2022
  • Figure 27. Regeneron Pharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Regeneron Pharmaceuticals Inc. (United States) Revenue: by Geography 2022
  • Figure 29. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Pfizer Inc. (United States) Revenue: by Geography 2022
  • Figure 31. Kubota Pharmaceutical Holdings Co. Ltd. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Kubota Pharmaceutical Holdings Co. Ltd. (United States) Revenue: by Geography 2022
  • Figure 33. Oculis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 34. Oculis (Switzerland) Revenue: by Geography 2022
  • Figure 35. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 36. Bayer AG (Germany) Revenue: by Geography 2022
  • Figure 37. Global Diabetic Macular Edema Treatment: by Type USD Million (2023-2028)
  • Figure 38. Global Diabetic Macular Edema Treatment: by Indication USD Million (2023-2028)
  • Figure 39. Global Diabetic Macular Edema Treatment: by Drug Delivery USD Million (2023-2028)
  • Figure 40. Global Diabetic Macular Edema Treatment: by End User USD Million (2023-2028)
  • Figure 41. South America Diabetic Macular Edema Treatment Share (%), by Country
  • Figure 42. Asia Pacific Diabetic Macular Edema Treatment Share (%), by Country
  • Figure 43. Europe Diabetic Macular Edema Treatment Share (%), by Country
  • Figure 44. MEA Diabetic Macular Edema Treatment Share (%), by Country
  • Figure 45. North America Diabetic Macular Edema Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • F. Hoffmann-La Roche AG (Switzerland)
  • Novartis AG (Switzerland)
  • GlaxoSmithKline plc (United Kingdom)
  • Alimera Sciences, Inc. (United States)
  • Allergan, Inc (Ireland)
  • Regeneron Pharmaceuticals Inc. (United States)
  • Pfizer Inc. (United States)
  • Kubota Pharmaceutical Holdings Co. Ltd. (United States)
  • Oculis (Switzerland)
  • Bayer AG (Germany)
Additional players considered in the study are as follows:
Bausch & Lomb Incorporated (United States) , Jaeb Center for Health Research (United States)
Select User Access Type

Key Highlights of Report


Nov 2023 201 Pages 61 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Diabetic Macular Edema Treatment Market Quantitative research analysis
Global Diabetic Macular Edema Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as F. Hoffmann-La Roche AG (Switzerland), Novartis AG (Switzerland), GlaxoSmithKline plc (United Kingdom), Alimera Sciences, Inc. (United States), Allergan, Inc (Ireland), Regeneron Pharmaceuticals Inc. (United States), Pfizer Inc. (United States), Kubota Pharmaceutical Holdings Co. Ltd. (United States), Oculis (Switzerland) and Bayer AG (Germany) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Surging R&D Investment by Pharmaceutical Companies in the Diabetic Macular Edema Treatment Field" is seen as one of major influencing trends for Diabetic Macular Edema Treatment Market during projected period 2022-2028.
The Diabetic Macular Edema Treatment market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Diabetic Macular Edema Treatment Market Report?

Have a Query? Click Here

Other Related Reports

Propionic Acidemia Comprehensive Study by Type (Neonatal-Onset PA, Late-Onset PA), Application (Hospitals & Clinics, Medicinal & Pharmaceutical Stores), Treatment Type (Carnitine Supplementation, Flu...
$ 3450
Ataxia-Telangiectasia Comprehensive Study by Distribution Channel (Hospital Pharmacies, Online Pharmacies), Diagnosis Type (IgA and Serum Alpha-1 Fetoprotein Levels, Genetic Testing), Treatment Type ...
$ 3350
Aplastic Anemia Treatment Comprehensive Study by Application (Adults, Kids), Disease Type (Acquired Aplastic Anemia, Inherited Bone Marrow Failure Syndromes (Inherited Aplastic Anemia)), Route of Adm...
$ 3750
Alexandrite Laser Treatment Comprehensive Study by Application (Aesthetic, Dermatology, Dentistry, Urology, Others), Indication (Vascular lesions, Pigmented lesions, Hair removal, Tattoo removal), En...
$ 3350
Fatty Acid Oxidation Disorder Comprehensive Study by Supplement Type (L-carnitine, L-carnitine, Medium Chain Triglyceride Oil), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online St...
$ 3750
Antiviral Combination Therapies Comprehensive Study by Type (Branded, Generic), Route of Administration (Oral, Intravenous), Indication (HIV, Hepatitis, Others), Drug Combination (NRTI/NNRTI, Integra...
$ 3450